Stay updated on Nivolumab and Cyclophosphamide for R/R AML Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.

Latest updates to the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page
- CheckyesterdayChange DetectedThe site revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe clinical trial record for nivolumab and oral cyclophosphamide in relapsed/refractory AML and higher-risk MDS is displayed, with study design, participant criteria, treatment details, outcomes, and supporting documents.SummaryDifference52%

- Check22 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2. The study record still shows a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA notice about NIH websites transitioning from “Artificial Intelligence” to “Super Intelligence” appears above the page content.SummaryDifference1%

- Check36 days agoChange DetectedThe footer revision identifier was updated from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check43 days agoChange DetectedThe footer’s site revision indicator changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

Stay in the know with updates to Nivolumab and Cyclophosphamide for R/R AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Cyclophosphamide for R/R AML Clinical Trial page.